Latest Lapatinib Stories

A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute. "We've revealed multiple new signaling pathways that regulate cell death," said Sally Kornbluth, PhD, vice dean of Basic Science and professor of Pharmacology and Cancer Biology at Duke...

Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine – at least for a certain population of women. In a report that appears online today in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of...

April Flowers for redOrbit.com - Your Universe Online The Food and Drug Administration (FDA) has approved a brand new type of breast cancer medication this week that targets tumor cells while sparing healthy surrounding tissues. In U.S. women, breast cancer is the second most deadly form of cancer and is expected to kill more than 39,000 Americans this year alone, the National Cancer Institute reports. Kadcyla, from Roche, is a combination of a powerful chemotherapy drug, the...

BURLINGTON, Mass., Feb. 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow eight percent annually over the next five years, from $1.7 billion to $2.5 billion. The market's growth can be attributed to the launch of several premium priced agents, a gradual increase in the use of...

CAMBRIDGE, Mass., Oct. 2, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the presentation of Phase 1 safety and clinical results evaluating two potential new therapies with a novel target - ErbB3, a signaling receptor believed to be responsible for triggering tumor growth and resistance in a number of malignancies including breast, ovarian, gastric, esophageal and bladder cancers. The two studies were presented in poster sessions at the European...

Two new studies presented at the ESMO 2012 Congress in Vienna, Austria show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy, but raise concerns about whether enough women are being offered these approaches. Prof Michael Gnant, a surgical oncologist from Vienna's Medical University, who was not involved in the studies, commented: "Clearly, advances in interdisciplinary preoperative approaches have contributed to...

Cancer Research Network studies anthracycline and trastuzumab in real-world care Women who have breast cancer and are treated with two chemotherapy drugs may experience more cardiac problems like heart failure than shown in previous studies, according to a new Cancer Research Network study by Group Health researchers and others in the Journal of the National Cancer Institute. The study is significant because more and more women are surviving longer with breast cancer, so it's becoming a...

NEW YORK, June 14, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials and drug intelligence, recently reviewed the results presented at the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL. A new type of targeted therapy was of particular interest to reviewer Daphna Halpern, Citeline's Director of Oncology: Antibody-Drug Conjugates (ADC's). According to Ms. Halpern, "ADC's are looking to...

Breakthrough Study Led by Rethink Breast Cancer Board Member TORONTO, June 4, 2012 /CNW/ - Today Rethink Breast Cancer (Rethink) celebrates new study results that bring hope to the more than 5,000 Canadian women living with HER2-positive breast cancer. The study, led by Dr. Sunil Verma, Medical Oncologist at Sunnybrook Odette Cancer Centre and Rethink Board Member, showed promising results for a new treatment for patients living with HER2-positive metastatic breast cancer...

A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening, various media outlets reported on Sunday. The drug, TDM-1, is manufactured by Roche, and according to Naomi Kresge and Robert Langreth of Bloomberg, it works by carrying chemotherapy directly into cancer cells while successfully avoiding healthy ones, resulting in fewer side effects than conventional treatments. According...